◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Syngene International Limited (SYNGENE) Financial History

Name: Syngene International Limited (SYNGENE) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Diagnostics & Research · DATA UPDATED 2026-09-20

Syngene International Limited (SYNGENE) operates in the Diagnostics & Research industry and is headquartered in Bengaluru, India with about 6,692 employees. Its market capitalization is roughly ₹149 billion. In the fiscal year ended 2026-03-31, SYNGENE reported ₹36.1B in revenue and ₹3.2B in net income.

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.

Interactive charts & full statements →

SYNGENE Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹36.1B	₹35.1B	₹33.7B	₹30.8B
Gross Profit	₹26.9B	₹25.7B	₹24.4B	₹22.2B
Operating Income (EBIT)	₹5.6B	₹6.1B	₹6.5B	₹6.2B
Net Income	₹3.2B	₹5.0B	₹5.1B	₹4.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYNGENE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Total Revenue	₹7.4B	₹10.4B	₹9.2B	₹8.7B	₹10.2B
Gross Profit	₹5.6B	₹8.0B	₹6.9B	₹6.6B	₹7.8B
Operating Income (EBIT)	₹287M	₹2.1B	₹1.2B	₹1.0B	₹2.4B
Net Income	(₹90M)	₹1.5B	₹150M	₹867M	₹1.8B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYNGENE Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹504M)	(₹503M)	(₹503M)	(₹401M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYNGENE Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹70.5B	₹68.0B	₹61.5B	₹58.3B	—
Total Liabilities	₹22.2B	₹20.7B	₹18.9B	₹22.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SYNGENE viewer.

Other Companies in Diagnostics & Research

SAILIFE · Sai Life Sciences Limited — ₹340 billion
LALPATHLAB · Dr. Lal PathLabs Limited — ₹317 billion
4544 · H.U. Group Holdings, Inc. — JPY 198 billion
VIJAYA · Vijaya Diagnostic Centre Limited — ₹161 billion
4694 · BML, Inc. — JPY 138 billion
METROPOLIS · Metropolis Healthcare Limited — ₹124 billion
2268 · WuXi XDC Cayman Inc. — HK$98 billion
THYROCARE · Thyrocare Technologies Limited — ₹88 billion

← SYNEX All “S” companies SYNT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.